Strategic Management Board
The Strategic Management Board's role is oversight and direction of the programme. Membership of the board will consist of stakeholders and advisors who will help guide the programme to a successful conclusion, delivering the strategic aims of the programme as set out in the proposal and delivering impact.
Professor Andrew Mount, FRSC - CHAIR
Professor Andy Mount is Professor of Physical Electrochemistry and Dean of Research in the College of Science & Engineering (CSE) at the University of Edinburgh.
His research interests include fundamental and applied electrochemistry, sensing and analysis and the development and application of healthcare and low carbon clean energy technologies; he has played a leading role in over £40million of major multidisciplinary collaborations across Scotland, the UK and Europe. As Director of Research he played a key role in the establishment of EaStCHEM, the joint chemistry research School of the Universities of Edinburgh and St Andrews, and he coordinated the highly successful CSE REF2014 submissions as Dean of REF. As Dean of Research he is now leading CSE research and impact strategy and development.
He is a Fellow of the Royal Society of Chemistry (RSC), Chair of the RSC Faraday Standing Committee on Conferences and a member of RSC Faraday Division Council. He is also member of the Science Advisory Committee of the Scottish Universities Environmental Research Centre, is external examiner for Chemistry degrees at the University of Warwick and was previously external examiner for Chemistry at the University of Bath.
Professor David Cameron
Prof. Cameron’s first degree was in mathematics from the University of Cambridge, and he received his medical degree in 1986 from St. George’s Hospital Medical School, London. After completing a fellowship and MSc in Clinical Oncology at the University of Edinburgh, he received a M.D. with distinction in 1997 and completed his training as a medical oncologist that same year. Prof. Cameron is a member of several professional societies including the American Society of Clinical Oncology & the European Society for Medical Oncology. He has also been a member of the EORTC task force on the use of growth factors in chemotherapy for solid tumours and lymphoma and a past chairman of the EORTC New Agent Committee. He is a past member of the Scottish medicines Consortium project and the Scottish short-life working group on the use of unlicensed cancer medicines.
He is active in a number of clinical trials in breast cancer. He is a member of the executive committee of the HERA adjuvant herceptin trial, and a member of the steering group for several UK adjuvant breast cancer trials (AZURE, OPTION, TACT, TANGO, MAMMO50, ARTEMIS, PERSEPHONE, ROSCO and TEAM) as well as the BIG APHINITY, ALTTO/NEO_ALTTO, BRAVO and AURORA studies. He is chief investigator on the recently reported UK trial adjuvant breast cancer trial, TACT2, and of BEATRICE, a global trial that tested the possible benefit of adjuvant bevacizumab in triple negative breast cancer. He jointly chairs the ENCHANT phase II study of an HSP90i in breast cancer.
Between November 2006 & June 2010 he was Director of the NIHR-funded National Cancer Research Networks, and at the end of 2009 took up a new post as Professor of Oncology at Edinburgh University and Director of Cancer Services in NHS Lothian. In this role he is the clinical director of the Edinburgh Cancer Research Centre (including the CRUK funded Edinburgh Cancer Centre and the joint Edinburgh-Dundee Experimental Cancer Medicine Centre), and has responsibility for oversight and strategy of clinical and translational research in cancer in Edinburgh. He continues his major clinical interest in breast cancer with an on-going clinical and translational research programme. He is a present and past member of several cancer research funding committees including INCA PHRC, PEAR, Cancer Research UK Science committee and from time to time NIHR funding bodies. He was recently appointed as the Chief Scientist’s Office Clinical Cancer Research Champion in Scotland to act as a focal point for current and future clinical research in cancer in Scotland.
Professor George Crooks, OBE
Professor George Crooks OBE MBChB FRCP FRCGP is currently the Chief Executive of the Digital Health and Care Institute, Scotland’s national innovation centre for digital health and care. He leads an organisation that is tasked with delivering innovation in digital health and care that will help Scotland’s people to live longer, healthier lives and create new jobs for the economy. DHI provides opportunities for Scotland’s public sector, academia, charities and industry to co-design digital solutions to some of the country’s biggest health and care challenges.
He was previously the Medical Director for NHS 24 and Director of the Scottish Centre for Telehealth & Telecare. George was a General Medical Practitioner for 23 years in Aberdeen latterly combining that role as Director of Primary Care for Grampian. George is on the Board of the European Connected Health Alliance. He is currently a Board member and past president of the European Health Telematics Association, andis on the Board of the European Foundation for Critical Care. He leads the Integrated Care Action Group on behalf of the European Commission within the European Partnership for Active and Healthy Ageing. He is Chair of the Scottish Digital Health and Care Innovation Programme Board, focussing on the adoption and delivery, at scale, of technology enabled care services across Scotland. He is also an adjunct Professor of Telehealth at the University of Southern Denmark.
He was awarded an OBE in the Queen's New Year Honours List 2011 for services to healthcare.
Dr Susanne Cruickshank
Dr Susanne Cruickshank qualified as an adult nurse at the Royal Infirmary, Edinburgh in 1987. She gained an MSc in Cancer Nursing from the University of Edinburgh in 2000 and her PhD in 2014. She is an Associate Professor in Cancer Nursing at the University of Stirling, Scotland and Chair of RCN Cancer and Breast Care UK Professional Forum. She has over 25 years’ clinical experience working in oncology and haematology; she started her clinical career caring for people undergoing surgery for head and neck cancer then moved into haematology and transplantation, breast cancer surgery and chemotherapy services.
She joined Edinburgh Napier University as a Lecturer in Cancer Nursing in 2003, progressing to Reader in 2011 and joined the University of Stirling in 2016. She is passionate about education and the opportunities it affords to promote the synergy between research, practice and policy. She is an active researcher and Chair of the Cancer Care Research Centre at the University of Stirling, a growing group of interdisciplinary researchers who seek to influence policy and healthcare decisions through research that focuses on how people live well with cancer. Her current work includes developing and evaluating complex interventions in clinical settings; specifically focusing on the impact of fear of the cancer recurring on an individual’s recovery, systematic appraisals of evidence that include supportive care and nursing roles, and mechanisms to improve the lives of people affected by cancer through effective translation of research into clinical practice.
Dr Cruickshank is also a member of the International Society of Nurses in Cancer Cares’ Corporate and Philanthropic Committee, Myeloma UK’s International Research Peer Review Panel, a UK safe handling of hazardous drugs group and past member of Breast Cancer NOW Scotland’s advisory panel.
Gillian has over 22 years’ experience working in the IT sector. Gillian is responsible for delivering the strategic vision set out by The Data Lab Board, the aim of which is to create over 250 new jobs and to generate more than £100 million to Scotland’s economy.
Prior to this Gillian held a range of Senior Leadership roles at IBM UK including Leader for Software Business in Scotland, Systems and Technology Sales Leader and Territory Leader for General Business Scotland.
Gillian is on the Board of Tech Partnership Scotland and is also a Board member of the Glasgow Chamber of Commerce. Gillian has a degree in Computing Science from Glasgow University and is married with a daughter.
Professor Aileen Keel, CBE
Aileen Keel is seconded from Scottish Government to the Usher Institute of Population Health Sciences and Informatics at the University of Edinburgh to lead the IHDP.
Aileen joined the Scottish Office (as was) as a Senior Medical Officer in the Department of Health in 1992.
She was Deputy Chief Medical Officer in Scottish Government Health and Social Care Directorates from 1999 to 2014. Between April 2014 and May 2015 she was acting Chief Medical Officer.
She is Chair of the Scottish Cancer Task Force, Co-chair of COMQI (Clinical Outcomes and Measures for Quality Improvement), and honorary consultant in haematology at Edinburgh Royal Infirmary and has an Honorary Chair at the University of Edinburgh.
Marian has a background in Business Development and Professional Relations working in large pharmaceutical companies, including Eli Lilly and Astra Zeneca. She has recently (2016) gained a Masters in Stratified Medicine and Pharmacological Innovation (with Merit) from the University of Glasgow. She has extensive experience of the medical marketing interface for oncology pipeline products and has been part of a large multi-disciplinary team focused on development through to successful launch of targeted treatments for cancer.
Sally Smith is Head of eHealth with responsibility for the development and delivery of the Board’s eHealth strategic vision.
With over 30 years experience as an IT Professional, Sally has significant understanding of the NHS Scotland technical and governance landscape, including applications, infrastructure and data.
Sally joined the Golden Jubilee Foundation in 2014 and is committed to delivering benefits to patients, carers and healthcare professionals through the adoption of innovative and technological solutions.
Dr Hester Ward
Dr. Hester Ward is a Consultant in Public Health Medicine at Information Services Division (ISD) & Health Protection Scotland (HPS), NHS National Services Scotland, and an Honorary Reader at the University of Edinburgh.
Hester provides public health leadership and expertise in the following areas focusing on information and intelligence: primary care, health and social care integration, unscheduled care and dementia, specifically Creutzfeldt-Jakob disease (CJD). Previously, she spent 10 years at the National CJD Research & Surveillance Unit undertaking epidemiological research into risk factors for CJD. She has been a member of an NHS Ethics’ Committee for over 10 years.
She is interested in facilitating the use of data, governed in a secure and proportionate way, for research and innovation to benefit the health of the population of Scotland.
Ian Welsh, OBE
Ian Welsh OBE is Chief Executive of the Health and Social Care Alliance Scotland and has extensive experience in the public, private and third sectors.
After the Penrose Inquiry, he Chaired the Scottish Government's Contaminated Blood Financial Review Group.
He served on the Court of the University of the West of Scotland, chairing its Policy and Resources Committee and completed his tenure as Chair of the Court
He was Director of UK Services for the Rehab Group, leading charities working in care, supported employment, rehabilitation and training.
As Chief Executive of Kilmarnock Football Club, he led the club through business and footballing success building a number of innovative community programmes.
He served as a non-executive Director of the Glasgow Prestwick Airport and as Executive Director of Human Resources and Public Affairs.
He serves on Ayrshire and Arran Health Board, chairing its Staff Governance Committee.
He is Chair of the East Ayrshire Health and Social Care Partnership
He is Chair of Microtech Group, Ayr Gaiety Partnership and the Ayr United Football Academy
In November 2016, he was conferred with an Honorary Doctorate by the University of the West of Scotland.
He currently sits on a range of Scottish Government Programme Boards.